Ladon deconvolution composition + L2 logistic regression (breast cancer pCR)
Twelve-class composition inferred by composition-post-trained Ladon from a breast tumour single-cell atlas reference, fed to an L2-penalised logistic regression of pathological complete response fitted on TransNEO.
Overview
An explanatory profile has not yet been reviewed for this record.
Consult the linked sources for architecture or protocol details. Missing evidence is not evidence of a missing capability.
Model Capabilities & Hardware Requirements
Deployment facts recorded for Ladon deconvolution composition + L2 logistic regression (breast cancer pCR). Fields the record does not carry are marked not recorded.
Evaluated Checkpoint: Composition-post-trained Ladon, as in the PBMC deconvolution configuration
Evaluations and results
4 evaluations · 4 results. Different protocols are not a single leaderboard.
Sorted by AUROC (AUC for pathological complete response, ER+/HER2- tumours, model fitted on TransNEO and applied unchanged) (higher is better). The best value in each column is highlighted. Decimals are rounded for display; each value links to the printed value and its source.
All 4 result rows with coverage, uncertainty and sources
Filter evaluations
Applied filters: All linked evaluations
| Tested configuration | Protocol and dataset | Finding | Evidence and details |
|---|---|---|---|
| Configuration: Ladon deconvolution composition + L2 logistic regression (breast cancer pCR) | Protocol: Breast cancer pCR, ER+/HER2- external cohorts, AUC of a model fitted on TransNEO Dataset subset: ARTEMIS ER+/HER2- patients (35, 3 pCR) | 0.9 AUROC (AUC for pathological complete response, ER+/HER2- tumours, model fitted on TransNEO and applied unchanged) unitless · higher Uncertainty: 95% CI 0.68 to 1.00. Percentile bootstrap resampling the cohort's patients; resamples with a single class discarded (page 39). Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceLadon deconvolution, ARTEMIS ER+/HER2-, pCR AUC ladon-20261115-protocol-pcr-er-pos-her2-neg-auc Aggregation: Not reported Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) · Figure 18 (page 35), panel 'ER+/HER2-' cohort 'ARTEMIS', row 'Ladon deconvolution', column 'AUC [95% CI]' |
| Configuration: Ladon deconvolution composition + L2 logistic regression (breast cancer pCR) | Protocol: Breast cancer pCR, HER2+ external cohorts, AUC of a model fitted on TransNEO Dataset subset: DFCI inflammatory breast cancer HER2+ patients (22, 9 pCR) | 0.73 AUROC (AUC for pathological complete response, HER2+ tumours, model fitted on TransNEO and applied unchanged) unitless · higher Uncertainty: 95% CI 0.50 to 0.93. Percentile bootstrap resampling the cohort's patients; resamples with a single class discarded (page 39). Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceLadon deconvolution, DFCI IBC HER2+, pCR AUC ladon-20261115-protocol-pcr-her2-pos-auc Aggregation: Not reported Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) · Figure 18 (page 35), panel 'HER2+' cohort 'DFCI IBC', row 'Ladon deconvolution', column 'AUC [95% CI]' |
| Configuration: Ladon deconvolution composition + L2 logistic regression (breast cancer pCR) | Protocol: Breast cancer pCR, ER+/HER2- external cohorts, AUC of a model fitted on TransNEO Dataset subset: PBCP ER+/HER2- patients (13, 3 pCR) | 0.97 AUROC (AUC for pathological complete response, ER+/HER2- tumours, model fitted on TransNEO and applied unchanged) unitless · higher Uncertainty: 95% CI 0.82 to 1.00. Percentile bootstrap resampling the cohort's patients; resamples with a single class discarded (page 39). Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceLadon deconvolution, PBCP ER+/HER2-, pCR AUC ladon-20261115-protocol-pcr-er-pos-her2-neg-auc Aggregation: Not reported Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) · Figure 18 (page 35), panel 'ER+/HER2-' cohort 'PBCP', row 'Ladon deconvolution', column 'AUC [95% CI]' |
| Configuration: Ladon deconvolution composition + L2 logistic regression (breast cancer pCR) | Protocol: Breast cancer pCR, HER2+ external cohorts, AUC of a model fitted on TransNEO Dataset subset: PBCP HER2+ patients (18, 11 pCR) | 0.82 AUROC (AUC for pathological complete response, HER2+ tumours, model fitted on TransNEO and applied unchanged) unitless · higher Uncertainty: 95% CI 0.53 to 1.00. Percentile bootstrap resampling the cohort's patients; resamples with a single class discarded (page 39). Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceLadon deconvolution, PBCP HER2+, pCR AUC ladon-20261115-protocol-pcr-her2-pos-auc Aggregation: Not reported Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) · Figure 18 (page 35), panel 'HER2+' cohort 'PBCP', row 'Ladon deconvolution', column 'AUC [95% CI]' |
Source checking is not independent reproduction. Release 2026-11-21-c8bea25e5abb.
Use this configuration
How it works, versions and access
Additional methodological details, versions and access terms have not yet been extracted into a structured profile for this configuration. Consult the linked sources and evaluation records below.
Evidence
Source checking verifies the cited claim or transcription. It does not establish independent reproduction.
Evidence table
Inspect claims, sources and review details
Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.
One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.
0 evidence rows matching the loaded filters
| Property and statement | Original source and location | Review and provenance |
|---|
No evidence rows match these filters. Choose another scope or clear the search.
Sources and history
Release 2026-11-21-c8bea25e5abb · Record review: source checked
1 source record and release history
- Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) · Original source · Zenodo record 24157116 (version DOI 10.5281/zenodo.24157116; concept DOI 10.5281/zenodo.24157115), file Ladon-An-RNA-Foundation-Model-for-Predicting-Patient-Outcomes.pdf, 47 pages, dated 12 November 2026
Technical metadata and record identifiers
Technical metadata for this record is tracked under stable ID ladon-20261115-config-ladon-composition-pcr.
Source locator: Pages 34, 35 and 40, Methods 'Breast cancer response prediction'
Related records
- configuration of: Ladon
- system: Ladon deconvolution, ARTEMIS ER+/HER2-, pCR AUC
- system: Ladon deconvolution, DFCI IBC HER2+, pCR AUC
- system: Ladon deconvolution, PBCP ER+/HER2-, pCR AUC
- system: Ladon deconvolution, PBCP HER2+, pCR AUC
How to cite
Ladon deconvolution composition + L2 logistic regression (breast cancer pCR). Rewire biological model benchmark database, release 2026-11-21-c8bea25e5abb. https://benchmarks.rewirebio.io/database/configuration/ladon-20261115-config-ladon-composition-pcr/
Release 2026-11-21-c8bea25e5abb. Rankings and values change between releases, so keep the release id in the citation. Cite the original publication as well for any value you reuse: each result links its source.
The compilation and annotations made by Rewire in this release are offered under CC BY 4.0; values and text taken from cited sources stay under the terms of those sources and are not covered by this licence. Data licence